For in vivo assays, mice were injected i.v. with 10 μg LPS (Sigma Aldrich), 200 μg imiquimod (Invivogen), or saline and killed 2 h later. Splenocytes were collagenase-treated and incubated in DMEM/10% FCS for 3 h in the presence of 10 μg/ml brefeldin A (Sigma-Aldrich), stained for surface markers, fixed, permeabilized, and stained with Allophycocyanin (APC)-conjugated anti–mouse IL-12 or an isotype control (BD Biosciences). For in vitro assays, splenocytes from untreated mice were enriched for a lineage-negative fraction and plated at 106 cells/well in 96-well round–bottom plates. Cells were treated with saline, 1 μg/ml LPS, 100 nM CpG (Invivogen), or 3 μg/ml imiquimod for 2 h and incubated for an additional 4 h in the presence of TLR ligands and brefeldin A. Cells were stained for surface markers, fixed, permeabilized, and stained with APC-conjugated anti–mouse IL-12, anti–mouse TNF-α, or isotype controls.
>
Chemicals & Drugs
>
Organic Chemical
>
Imiquimod
Imiquimod
Imiquimod is a synthetic immune response modifier used topically for the treatment of certain skin conditions.
It acts by stimulating the immune system to produce cytokines, which can help fight off viral infections and cancer cells.
Imiquimod is approved for the treatment of actinic keratosis, superficial basal cell carcinoma, and genital warts.
It may also be used off-label for other dermatological conditions.
Proper use and monitoring by a healthcare provider is important to ensure the safe and effective use of imiquimod in research and clinical settings.
It acts by stimulating the immune system to produce cytokines, which can help fight off viral infections and cancer cells.
Imiquimod is approved for the treatment of actinic keratosis, superficial basal cell carcinoma, and genital warts.
It may also be used off-label for other dermatological conditions.
Proper use and monitoring by a healthcare provider is important to ensure the safe and effective use of imiquimod in research and clinical settings.
Most cited protocols related to «Imiquimod»
allophycocyanin
Biological Assay
Brefeldin A
Cells
Collagenase
Imiquimod
Immunoglobulin Isotypes
Interleukin-12
Ligands
Mus
Saline Solution
Tumor Necrosis Factor-alpha
Allantois
Buffers
Centrifugation
Chickens
Chinese
Dental Caries
Eggs
Emulsions
Imiquimod
Iodine
Levamisole Hydrochloride
Oil, Mineral
Pharmaceutical Adjuvants
Phosphates
Poly A
Propiolactone
Protein Isoforms
resiquimod
Specific Pathogen Free
Strains
Vaccines
Virus
The study protocol involving the use of human blood cells was approved by the Ethics Committee of the University of Naples Federico II. Cells were isolated from buffy coats of healthy donors. Blood was layered onto Histopaque-1077 (Sigma-Aldrich) and mononuclear cells were collected at the interface. Monocytes were further purified with anti-CD14 Microbeads (Miltenyi Biotec). Purity of cell preparations was >95% as assessed by flow cytometry. Cells were cultured in cIMDM-5 [IMDM, 5% FCS, 1× non-essential amino acids, 1× UltraGlutamine, 25 mM HEPES, 5 µg/mL gentamicin (Lonza)] in 96-well flat-bottom plates (105 monocytes/well) in a final volume of 250 µL. For experiments involving flow cytometry, cells were cultured in suspension (1.5 mL tubes) in cIMDM-5 at a concentration not greater than 2 × 106 cells/mL, then spun down and collected for subsequent experiments.
Cells were treated with different combinations of: LPS (Escherichia coli 026:B6) 10 ng/mL (Sigma-Aldrich), IL-3 5 ng/mL (Peprotech), M-CSF 25 ng/mL, GM-CSF 5 ng/mL (Miltenyi Biotec), P3CSK4 10 ng/mL, Poly(I:C) 1 µg/mL, flagellin 10 ng/mL, imiquimod 1 µg/mL, ODN2006 1 µM (Invivogen), BAY11-7082 1 µM, SP600125 2 µM, rapamycin 50 and 250 nM, torin1 10 and 50 nM, AGK2 10 µM, APO866 0.1, 1, and 10 nM, TG101348 125, 250, and 500 nM (Selleckchem), U0126 2 µM, LY294002 10 µM, SB203580 2 µM (Cell Signaling Technology), 10058-F4 40 µM, EX-527 500 nM (Tocris Bioscience), 2-Deoxy-d -Glucose 1 mM, Etomoxir 40 µM, BAY 85-3934 1 µM, CAY-10585 10 µM (Cayman Chemical), nicotinic acid 10 µM (Sigma-Aldrich), Pyridone 6 100 nM (BioVision), Trichostatin A (TSA) 5 nM (Calbiochem).
Cells were treated with different combinations of: LPS (Escherichia coli 026:B6) 10 ng/mL (Sigma-Aldrich), IL-3 5 ng/mL (Peprotech), M-CSF 25 ng/mL, GM-CSF 5 ng/mL (Miltenyi Biotec), P3CSK4 10 ng/mL, Poly(I:C) 1 µg/mL, flagellin 10 ng/mL, imiquimod 1 µg/mL, ODN2006 1 µM (Invivogen), BAY11-7082 1 µM, SP600125 2 µM, rapamycin 50 and 250 nM, torin1 10 and 50 nM, AGK2 10 µM, APO866 0.1, 1, and 10 nM, TG101348 125, 250, and 500 nM (Selleckchem), U0126 2 µM, LY294002 10 µM, SB203580 2 µM (Cell Signaling Technology), 10058-F4 40 µM, EX-527 500 nM (Tocris Bioscience), 2-Deoxy-
Full text: Click here
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one
Amino Acids, Essential
APO 866
BAY 11-7082
BAY 85-3934
BLOOD
Caimans
Cells
Donors
Escherichia coli
Ethics Committees
etomoxir
EX 527
Flagellin
Flow Cytometry
Gentamicin
Glucose
Granulocyte-Macrophage Colony-Stimulating Factor
HEPES
histopaque
Homo sapiens
Imiquimod
LY 294002
Macrophage Colony-Stimulating Factor
Microspheres
Monocytes
N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine
Niacin
ODN2006
oxytocin, 1-desamino-(O-Et-Tyr)(2)-
Poly I-C
SB 203580
Sirolimus
SP600125
TG101348
trichostatin A
U 0126
2-Mercaptoethanol
Amino Acids, Essential
Bone Marrow Cells
Buffers
Cells
cyclic guanosine monophosphate-adenosine monophosphate
DNA, Viral
Enzyme-Linked Immunosorbent Assay
Glutamine
Granulocyte-Macrophage Colony-Stimulating Factor
HEPES
Imiquimod
lipofectamine 2000
Macrophage Colony-Stimulating Factor
Mus
Pneumonias, Pneumococcal
Pyruvate
Salmonella
Sodium
Streptococcal Infections
Tumor Necrosis Factor-alpha
Vaccinia virus
The TLR7 agonist SZU-101 was synthesised as described in Additional file 2 : Figure S2. HEK-BLUE hTLR7 cells were purchased from InvivoGen. The cells stably expressed human TLR7 and a SEAP reporter, which can be used to detect TLR7 agonism through the activation of NF-kB signalling. The cells were maintained in selective DMEM growth medium with an additional 10 μg/ml blasticidin and 100 μg/ml Zeocin™. After incubation with different doses of SZU-101, the cells were tested using the HEK-BLUE detection kit according to the manufacturer’s instructions. The TLR7 agonist imiquimod and purified mouse TNF-α were used as positive controls. The induction of TLR7 activation can be visualised and assessed by reading the OD at 620–655 nm.
Full text: Click here
agonists
Cells
Culture Media
Homo sapiens
Imiquimod
Mus
NF-kappa B
SZU-101
TLR7 protein, human
Tumor Necrosis Factor-alpha
Zeocin
Most recents protocols related to «Imiquimod»
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
agonists
BLOOD
Buffers
Cell Culture Techniques
Cells
Enzyme-Linked Immunosorbent Assay
Imiquimod
Interleukin-1 beta
Lipopolysaccharides
Pellets, Drug
Protease Inhibitors
Proteolysis
Radioimmunoprecipitation Assay
SERPINB5 protein, human
Sterility, Reproductive
Tumor Necrosis Factor-alpha
Ultrasonics
An imiquimod (IMQ)-induced psoriasis-like dermatitis murine model was induced by topical administration of IMQ cream (62.5 mg/day for 7 days) on the right flank skin (1.5 × 1.5 cm area) that had been previously depilated. XPO and DXM were topically applied (daily for 5 days) 4 h after IMQ application. Control mice were treated with Vaseline cream. The used compounds were dissolved in a cream of vegetable origin.
Full text: Click here
Administration, Topical
Dermatitis
Imiquimod
Mus
Psoriasis
Skin
Vaseline
Vegetables
The content of the drug substance was analyzed per High performance liquid chromatography (HPLC)-UV using a Jasco HPLC equipped with a LC-Net II/ADC interface box, an Autosampler AS-950, a PU-980 pump, an UV/VIS UV-975 detector, a DG980-50 degasser, a LG-980-50 mixer and a Jet Stream ATP-CHY 501 column oven. ChromNav CFR 2 software was used to integrate and analyze the generated peaks of the chromatograms. As the analytical method, the method from the USP Monograph Imiquimod Cream Assay was used [24 ] (for details, see S1 ). Acceptance criterion 90% ≤ × ≤ 110% of labeled amount.
Full text: Click here
Biological Assay
High-Performance Liquid Chromatographies
Imiquimod
Pharmaceutical Preparations
BALB/c mice were utilised in the in vivo studies. Test animals were kept at a temperature condition of 25 ± 2 °C, with relative humidity of 45% ± 5% for 12 h of dark and light cycle with no curtailing of food and drink. BALB/c mice were distributed into 6 groups, each with 5 animals. Hair was removed from the dorsal surface of the mice using Veet hair removal cream, and psoriasis was induced by applying Imiquimod cream 5% daily [49 (link),50 (link)] (12.5 mg) on each mouse’s shaved left ear and back for eight days. Except for the control normal mice group, details can be found in Table 2 . The clinical Psoriasis Area and Severity Index (PASI) was identified as the best grading system based on the severity of inflammation. After eight days of treatment, animals were subject to cervical dislocation, and skin and spleen were removed and kept in a 10% formalin solution. Haematoxylin/eosin dye was used for staining the samples. These samples were compared to a control skin sample under a light microscope (Motic digital microscope, DMB series) [51 (link)].
Full text: Click here
Aftercare
Animals
Depilation
Eosin
Fingers
Food
Formalin
Hair
Hematoxylin
Humidity
Imiquimod
Inflammation
Joint Dislocations
Light Microscopy
Mice, Inbred BALB C
Microscopy
Mus
Neck
Psoriasis
Skin
Spleen
The FA was received as a gift sample from NZ Fulvic Ltd., New Zealand. TQ, DPPH, and Rhodamine B were purchased from Sigma-Aldrich (Darmstadt, Germany). Transcutol P, Capryol 90, Labrasol, Plurol, Polyethylene glycol, Tween 20, Tween 80, and PEG 200 were obtained from Gattefosse Pvt. Ltd., Mumbai, India as gift samples. TNF-α and IL-6 ELISA Kits were purchased from Krishgen Biosystem (Mumbai, India). Imiquimod (IMQ) 5% cream (Glenmark Pharmaceuticals Ltd. Imiquad®, (Delhi, India) was purchased from a local pharmacy. Castor oil, Kalonji oil, lavender oil, sunflower oil, and olive oil were procured from local market, and Carbopol-971 was purchased from GLR Innovations India Pvt. Ltd. (New Delhi, India). All other chemicals and solvents used were of analytical grade.
Full text: Click here
capryol-90
Carbopol
Castor oil
Enzyme-Linked Immunosorbent Assay
Imiquimod
Innovativeness
Labrasol
lavender oil
Nigella sativa
Oil, Olive
Oil, Sunflower
Pharmaceutical Preparations
Polyethylene Glycols
rhodamine B
Solvents
transcutol P
Tumor Necrosis Factor-alpha
Tween 20
Tween 80
Top products related to «Imiquimod»
Sourced in United States, France, Germany
Imiquimod is a synthetic compound that acts as a toll-like receptor 7 (TLR7) agonist. It is used as a tool in laboratory research settings to study immune function and signaling pathways.
Sourced in United States, France, Germany, Canada, China, Spain, Hong Kong, United Kingdom
Poly(I:C) is a synthetic double-stranded RNA (dsRNA) molecule that mimics the structure of viral RNA. It acts as an agonist of Toll-like receptor 3 (TLR3), triggering an innate immune response similar to that induced by viral infection.
Sourced in United States, France, United Kingdom, Canada, Germany, Sweden, Italy, Macao
Pam3CSK4 is a synthetic triacylated lipopeptide that mimics the structure of the acylated amino terminus of bacterial lipoproteins. It acts as a potent agonist of Toll-like receptor 2 (TLR2) and can be used in cell-based assays to study TLR2-mediated cellular responses.
Sourced in United States, Germany
Imiquimod is a laboratory product manufactured by Merck Group. It is a synthetic compound used for research purposes. Imiquimod is an immune response modifier that has been found to have potential applications in various areas of study.
Sourced in United States
Imiquimod (R837) is a synthetic imidazoquinoline compound. It is a Toll-like receptor 7 (TLR7) agonist that can activate the innate immune system.
Sourced in United States, Germany, China, United Kingdom, Sao Tome and Principe, Macao, Italy, Japan, Canada, France, Switzerland, Israel, Australia, Spain, India, Ireland, Brazil, Poland, Netherlands, Sweden, Denmark, Hungary, Austria, Mongolia
The LPS laboratory equipment is a high-precision device used for various applications in scientific research and laboratory settings. It is designed to accurately measure and monitor specific parameters essential for various experimental procedures. The core function of the LPS is to provide reliable and consistent data collection, ensuring the integrity of research results. No further details or interpretations can be provided while maintaining an unbiased and factual approach.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States
Flagellin is a structural protein found in the flagella of bacteria. It is a key component of the bacterial flagellum, which is responsible for the motility of many bacterial species. Flagellin plays a crucial role in the assembly and function of the flagellum, enabling bacteria to move and navigate their environment.
Sourced in United States, France, United Kingdom, Canada, China, Australia, Germany
LPS is a laboratory product that functions as a key component in cell culture and biological research. It serves as a widely used tool for the study of immune responses and inflammation.
Sourced in United States, France, Australia
FSL-1 is a synthetic ligand for the Toll-like receptor 7 (TLR7). It is a potent inducer of Type I interferon production and can be used to stimulate innate immune responses in cell-based assays.
More about "Imiquimod"
Imiquimod, also known as R-837 or Aldara, is a synthetic immune response modifier that has been widely studied and utilized in the treatment of various skin conditions.
As a potent immune stimulant, imiquimod acts by triggering the production of cytokines, which are signaling molecules that enhance the body's natural defense mechanisms against viral infections and cancer cells.
Imiquimod has been approved for the treatment of actinic keratosis, a precancerous skin condition, as well as superficial basal cell carcinoma and genital warts.
However, its applications extend beyond these approved indications, with off-label use in the management of other dermatological conditions, such as molluscum contagiosum, lentigo maligna, and even certain types of skin lymphomas.
The mechanism of action of imiquimod involves the activation of Toll-like receptor 7 (TLR7), which is expressed on various immune cells, including dendritic cells, macrophages, and natural killer cells.
This activation leads to the production of cytokines, such as interferon-alpha, interleukin-6, and tumor necrosis factor-alpha, which contribute to the antiviral and antitumor effects of imiquimod.
In addition to imiquimod, other immune response modifiers, such as Poly(I:C), Pam3CSK4, and Flagellin, have also been studied for their potential therapeutic applications.
These compounds, like imiquimod, target specific pattern recognition receptors (PRRs) on immune cells, triggering the release of cytokines and stimulating the immune system.
When conducting research on imiquimod or other immune response modifiers, it is important to consider factors such as the appropriate cell culture conditions, including the use of fetal bovine serum (FBS) and the selection of relevant cell lines or animal models.
Additionally, the inclusion of appropriate positive and negative controls, as well as the careful monitoring of experimental outcomes, can help ensure the reproducibility and reliability of your research findings.
By leveraging the insights and techniques provided by PubCompare.ai, researchers can optimize their imiquimod-related protocols, identify the most effective and reproducible approaches, and ultimately advance the understanding and therapeutic applications of this versatile immune response modifier.
As a potent immune stimulant, imiquimod acts by triggering the production of cytokines, which are signaling molecules that enhance the body's natural defense mechanisms against viral infections and cancer cells.
Imiquimod has been approved for the treatment of actinic keratosis, a precancerous skin condition, as well as superficial basal cell carcinoma and genital warts.
However, its applications extend beyond these approved indications, with off-label use in the management of other dermatological conditions, such as molluscum contagiosum, lentigo maligna, and even certain types of skin lymphomas.
The mechanism of action of imiquimod involves the activation of Toll-like receptor 7 (TLR7), which is expressed on various immune cells, including dendritic cells, macrophages, and natural killer cells.
This activation leads to the production of cytokines, such as interferon-alpha, interleukin-6, and tumor necrosis factor-alpha, which contribute to the antiviral and antitumor effects of imiquimod.
In addition to imiquimod, other immune response modifiers, such as Poly(I:C), Pam3CSK4, and Flagellin, have also been studied for their potential therapeutic applications.
These compounds, like imiquimod, target specific pattern recognition receptors (PRRs) on immune cells, triggering the release of cytokines and stimulating the immune system.
When conducting research on imiquimod or other immune response modifiers, it is important to consider factors such as the appropriate cell culture conditions, including the use of fetal bovine serum (FBS) and the selection of relevant cell lines or animal models.
Additionally, the inclusion of appropriate positive and negative controls, as well as the careful monitoring of experimental outcomes, can help ensure the reproducibility and reliability of your research findings.
By leveraging the insights and techniques provided by PubCompare.ai, researchers can optimize their imiquimod-related protocols, identify the most effective and reproducible approaches, and ultimately advance the understanding and therapeutic applications of this versatile immune response modifier.